Samenvatting
Medulloblastoma (MB) is a highly malignant pediatric brain tumor. Despite aggressive therapy, many patients succumb to the disease, and survivors experience severe side effects from treatment. MYC-driven MB has a particularly poor prognosis and would greatly benefit from more effective therapies. We used an animal model of MYC-driven MB to screen for drugs that decrease viability of tumor cells. Among the most effective compounds were histone deacetylase inhibitors (HDACIs). HDACIs potently inhibit survival of MYC-driven MB cells in vitro, in part by inducing expression of the FOXO1 tumor suppressor gene. HDACIs also synergize with phosphatidylinositol 3-kinase inhibitors to inhibit tumor growth in vivo. These studies identify an effective combination therapy for the most aggressive form of MB.
Originele taal-2 | Engels |
---|---|
Pagina's (van-tot) | 311-323 |
Aantal pagina's | 13 |
Tijdschrift | Cancer Cell |
Volume | 29 |
Nummer van het tijdschrift | 3 |
DOI's | |
Status | Gepubliceerd - 14 mrt. 2016 |
Extern gepubliceerd | Ja |